Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome

Documenti analoghi

• Stability of Classification Systems for Irritable Bowel Syndrome
  di: Mais Khasawneh, et al.
  Pubblicazione: (2025)
• Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome
  di: Mohsin F. Butt, et al.
  Pubblicazione: (2024)
• Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
  di: Kee Huat Chuah, et al.
  Pubblicazione: (2025)
• The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance
  di: T. E. Conley, et al.
  Pubblicazione: (2026)
• Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care
  di: Vivek C. Goodoory, et al.
  Pubblicazione: (2026)